Last month, a retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS) ...

LONDON — Treatment with the antidepressant fluoxetine does not decrease progression in multiple sclerosis (MS), results of a new randomized controlled trial show. First results released from the FLUOX ...

Multiple Sclerosis (MS) is an autoimmune, inflammatory condition of the central nervous system. Relapsing MS (formerly known as Relapsing Remitting MS) is the most common form and constitutes ...

A minority of patients with multiple sclerosis (MS) have primary progressive disease, and it has few treatment options. The challenges of developing treatments for primary progressive multiple ...